Online inquiry

IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4344MR)

This product GTTS-WQ4344MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL5RA gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000564.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3568
UniProt ID Q01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4344MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13172MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ11153MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ7879MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ3717MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ1721MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ14323MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ3740MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ12682MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-18R5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW